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Abstract
Objective: Immunological studies have demonstrated a plethora of beneficial
effects of dimethyl fumarate (DMF) on various cell types. However, the cellular
and molecular targets are incompletely understood and response markers are
scarce. Here, we focus on the relation between nuclear factor (erythroid-derived
2)-like 2 (NRF2) pathway induction under DMF therapy and the composition
of the blood immune cell compartment and clinical efficacy in relapsing-remit-
ting multiple sclerosis (MS) patients. Methods: We explored effects of DMF on
peripheral immune cell subsets by flow cytometric and transcriptional analysis
of serial blood samples obtained from 43 MS patients during the first year of
therapy. Results: Gene expression analysis proved activation of NRF2 signaling
under DMF therapy that was paralleled by a temporal expansion of FoxP3+ reg-
ulatory T cells, CD56bright natural killer cells, plasmacytoid dendritic cells, and a
decrease in CD8+ T cells, B cells, and type 1 myeloid dendritic cells. In a sub-
group of 28 patients with completely available clinical data, individuals with
higher levels of the NRF2 target gene NAD(P)H quinone dehydrogenase 1
(NQO1) 4–6 weeks after DMF therapy initiation were more likely to achieve
no evidence of disease activity status 1 year later. The degree of NQO1 induc-
tion further correlated with patient age. Interpretation: We demonstrate that
positive effects of DMF on the clinical outcome are paralleled by induction of
the antioxidant NRF2 transcriptional pathway and a shift toward regulatory
immune cell subsets in the periphery. Our data identify a role of the NRF2
pathway as potential biomarker for DMF treatment in MS.
Introduction
Multiple sclerosis (MS) is the most frequent chronic neu-
roinflammatory disease of the central nervous system
(CNS) that leads to multifocal demyelinated lesions in the
brain and spinal cord.1,2 Studies using the mouse model
of MS, experimental autoimmune encephalomyelitis
(EAE), suggest a correlation between disease
development/progression and activation of T helper (Th)
1, Th17 cells, and CNS infiltrating CD8+ T cells, B lym-
phocytes, natural killer (NK) cells, and myeloid cells
which participate in inflammation and tissue damage.3 A
major therapeutic goal in treating MS is to re-establish
tolerance toward the CNS, which may be achieved not
only through directly inhibiting the development of
autoreactive Th1 and Th17 cells but also by skewing
668 ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
immune system responses toward Th2 or Treg cell func-
tions via modulating antigen-presenting cells (APC).
Dimethyl fumarate (DMF) is an oral formulation of
fumaric acid esters that has been approved for the treat-
ment of relapsing-remitting MS based due to its highly
significant effects on relapses, disability progression, and
CNS lesions.4–7
We and others have shown that clinical effects of DMF
involve immunomodulatory and direct antioxidant
actions on the CNS as well as neuroprotection.8,9 DMF
reduces cytokine production,10 downregulates the migra-
tory activity of immune cells at the blood–brain barrier11
and activates the nuclear factor (erythroid-derived 2)-like
2 (NRF2) transcriptional pathway.8,12 The antioxidant
transcription factor NRF2 was described as critical regula-
tor responsible for maintenance of redox homeostasis and
prevention of oxidative stress by modulating the expres-
sion of cytoprotective genes, such as NAD(P)H quinone
dehydrogenase 1 (NQO1), Aldo-keto reductase family 1
member C1 (AKR1C1), and glutathione.13,14 However,
other studies demonstrated that DMF treatment also pro-
moted immune modulation and provided clinical benefits
in Nrf2 knockout mice suggesting an anti-inflammatory
activity of DMF through alternative pathways, indepen-
dent of Nrf2.15 For example, DMF is a potent agonist of
the hydroxycarboxylic acid receptor 2 (HCAR2) which is
also essential for DMF efficacy in the animal model.16,17
Although immunological studies show that DMF has a
plethora of beneficial effects on various cell types in the
CNS and periphery, the cellular and molecular target
structures are not fully understood. In this study, we
focus on the relation of NRF2 pathway induction under
DMF therapy to the composition of the blood immune
cell compartment and clinical efficacy in MS patients.
Material and Methods
Patients and sample collection
The study was approved by the Ethics Committee of the
Friedrich-Alexander University Erlangen-N€urnberg (no.
81_15B). Written informed consent was obtained from all
participants in accordance with the Declaration of Hel-
sinki. To allow inclusion in this study, patients were
required to be >18 years and diagnosed with relapsing-
remitting MS according to the revised McDonald crite-
ria.18 Patients were excluded in case of immunization <3
months or clinical evidence of ongoing bacterial infection.
The majority of patients were treatment-na€ıve to disease-
modifying drugs (60.5%) or switching from an ongoing
interferon-beta or glatiramer acetate therapy; 44.2% per-
cent of participants had been newly diagnosed within the
year preceding initiation of Tecfidera therapy. The
median age was 34a (20–63a) with a female to male ratio
of 2.58 (see also Table 1). At each visit, number of
relapses, clinical course, DMF side effects, concomitant
medication, and Expanded Disability Status Scale (EDSS)
were recorded. Furthermore, MRI data were collected.
Peripheral blood was obtained by venipuncture using
EDTA prefilled tubes for PBMC analysis or PAXgene
blood RNA tubes (Qiagen, Venlo, Netherlands) before
initiation of therapy (T0), after 4–6 weeks (T1), 3 months
(T2), 6 months (T3), and 12 months (T4) of Tecfidera
treatment. In addition, age and sex-matched healthy
donors (HD) were recruited for blood donation.
Isolation and phenotyping of PBMC
PBMC were isolated by density gradient centrifugation
(Lymphoprep; Axis Shield, Oslo, Norway). 1 9 106
PBMC were incubated with fixable viability dye eFlu-
or780 (eBioscience), FcR block (Miltenyi), and the
respective fluorochrome-conjugated antibodies: aCD3-
eFluor450 (UCHT1, eBioscience), aCD4-eFluor450 (SK3,
Biolegend), aCD8-APC (SK1, BD Biosciences), aCD19-
PE/Cy7 (HIB19, Biolegend), aCD56-PE (HCD56, Biole-
gend), aFoxp3-PE (206D, Biolegend), aIFNc-APC (B27,
BD Biosciences), aIL-4-FITC (MP4-25D2, Biolegend),
aIL-17A-PE (eBio64DEC17, eBioscience), and analyzed
on a BD FACSCantoII using FACSDiva software. For
intracellular cytokine staining, cells were prestimulated for
3h with ionomycin (1 lmol/L, Sigma-Aldrich) and
PMA (50 ng/mL, Sigma-Aldrich) in the presence of
monensin (2 lmol/L, eBioscience), fixed and made per-
meable with the Fixation/Permeabilization buffer set
(eBioscience) according to the manufacturer’s protocol.
Peripheral blood DC were analyzed for the expression
of CD1c (BDCA-1), CD303 (BDCA-2), and CD141
(BDCA-3) with the Blood Dendritic Cell Enumeration Kit
(Miltenyi) in a subset of patients (frozen samples) accord-
ing to the manufacturer0s instructions.
Table 1. Baseline demographic and disease characteristics of the
study cohort.
Characteristic
Patient cohort
(n=43)
Age, mean (SD) 36.3 (11.7)
Female, n (%) 31 (72.1)
Newly diagnosed within previous year, n (%) 19 (44.2%)
Patients with prior treatment, n (%) 17 (39.5%)
Interferon b, n (%) 11 (25.6%)
Glatiramer acetate, n (%) 6 (13.9%)
Patients with relapses in prior year, n (%) 30 (69.8%)
EDSS score, median (IQR) 1.5 (1.0)
SD, standard deviation; IQR, interquartile range; EDSS, Expanded Dis-
ability Status Scale.
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Real-time PCR
PCR reactions were performed with a qTower real-time
PCR System (Analytik Jena, Jena, Germany). Relative quan-
tification was performed by the DDCT method, normalizing
target gene expression on GAPDH as housekeeping gene.
The following TaqMan real-time PCR assays from Thermo
Fisher Scientific were used: KEAP1 Hs00202227_m1,
NFE2L2 Hs00975961_g1, NQO1 Hs02512143_s1, AKR1C1
Hs04230636_sH, HMOX1 Hs01110250_m1, HCAR2
Hs02341584_s1, GAPDHHs02758991_g1.
Statistical analysis
Statistical testing was performed using GraphPad Prism
(GraphPad Software Inc, San Diego, California). All data
were analyzed by either unpaired t-test, one-way ANOVA
followed by Dunnett’s posttest, or linear regression analy-
sis after checking for normal distribution (unless other-
wise indicated). Statistical significance was tested between
T0 and the different time points after DMF treatment.
HD were not included in the statistical analysis as indi-
cated by dotted lines. Data are presented as
mean  SEM; *P < 0.05, **P < 0.01, or ***P < 0.001
were considered to be statistically significant.
Results
DMF therapy induces the NRF2
transcriptional pathway in PBMC
Gene expression analyses from whole blood samples of
DMF-treated patients showed a transient increase in
KEAP1 (Kelch-like ECH-associated protein 1) and NRF2
(NFE2L2) mRNA as well as elevated levels of the NRF2
target genes NQO1 and AKR1C1 (Fig. 1A–D) but not
HO-1 (Fig. S1A) that was most pronounced 4–6 weeks
after initiation of therapy. In contrast, the expression level
of HCAR2, a niacin receptor involved in the regulation of
inflammation and oxidative stress independently from
NRF2 signaling, was not altered during the course of
treatment (Fig. 1E).
DMF increases the frequencies of regulatory
immune cell subsets in MS patients
Circulating FoxP3+ Tregs transiently increased following
DMF treatment initiation with peak levels 3 months after
therapy induction (T2) (Fig. 2A). FoxP3+ Treg frequen-
cies returned to baseline after 1 year of therapy (T4)
(Fig. 2A), while the proportion of regulatory CD56bright
NK cells was observed to gradually rise during the obser-
vation period (Fig. 2B). Similar observations were made
for plasmacytoid dendritic cells (pDC), whereas type 1
myeloid dendritic cells (mDC) but not type 2 mDC were
significantly decreased during the first 3 months
(Fig. 2C–E). The frequency of total CD4+ T cells started
to increase after 6 months of therapy (Fig. 2F), whereas
the percentages of Th1, Th2, and Th17 differentiated cells
as well as CD56dim NK cells remained stable in our longi-
tudinal analysis (Fig. 2G–J). In line with other publica-
tions, DMF therapy was associated with reduced CD8+ T
cell and B cell counts among total PBMC (Fig. 2K and
L).19–21
In accordance with cell frequencies, cell counts of
mDC1, CD8+ T cells, and B cells were significantly
reduced during DMF therapy (Fig. S2). CD56bright NK
cells were slightly increased after 1 year of treatment,
whereas pDC and Treg cell counts remained stable at least
until 6 months (Fig. S2). Therefore, the observed increase
in Treg, pDC, and CD56bright NK cell frequencies may
rather result from a relative reduction in other cell
counts.
Immune effects and clinical outcome of
DMF therapy correlate with NRF2
transcriptional pathway induction
DMF treatment significantly reduced the absolute lym-
phocyte count in 21 of 24 patients by 0.59  0.49 9 103/
lL (Table 2). Still, the mean absolute lymphocyte number
remained within the normal range (1.2  0.5 9 103/lL).
During the first year of therapy, 22 of 28 (78.6%) patients
showed no new MRI lesions, 19/28 (67.9%) patients had
no relapses, and the EDSS remained stable in 16 out of
28 (57.1%) patients. In the end, 9 of 28 (32.1%) patients
gained no evidence of disease activity (NEDA) status
(Table 2).
Since the transcription factor NRF2 is mainly regulated
via its binding to KEAP1, which is followed by proteaso-
mal degradation,22 and not by alterations on the mRNA
level, we used the NRF2 target gene NQO1 to further
analyze the NRF2 transcriptional pathway as potential
early biomarker for DMF treatment effectiveness. Patients
who achieved NEDA after 1 year of therapy showed sig-
nificantly higher NQO1 expression levels after 4–6 weeks
and a trend toward higher Treg frequencies during the
first 3 months of the study (Fig. 3A and B). Furthermore,
the observed increase in Treg frequencies at time point
T2 significantly correlated with the degree of NQO1
induction (Fig. 3C).
Interestingly, also the age of the patient at the time of
treatment initiation showed a trend to influence the
chance to achieve NEDA (Fig. 3D). Moreover, patient age
negatively correlated with the degree of NQO1 and Treg
induction following DMF treatment (Fig. 3E and F). In
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Figure 1. DMF induces the NRF2 transcriptional pathway but not HCAR2 expression in PBMC. mRNA expression levels of KEAP1 (A), NFE2L2
(NRF2), (B) and its target genes NQO1 (C) and AKR1C1 (D) as well as HCAR2 (E) were analyzed by qRT-PCR (9–11 HD and 25–30 DMF-treated
MS patients per time point, *P < 0.05, **P < 0.01, ***P < 0.001). HD, healthy donor; baseline (T0), 4–6 weeks (T1), 3 months (T2), 6 months
(T3), and 1 year (T4) of DMF intake.
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contrast, NQO1 levels did not correlate with EDSS score
(Fig. S3), lymphocyte counts, treatment discontinuation,
or side effects (data not shown). Levels of AKR1C1 and
HO-1 expression shortly after treatment onset did not
correlate with NEDA status or Treg frequency, however,
AKR1C1 induction showed a trend to be reduced with
increasing patient age (Fig. S1 and S4).
Discussion
Here, we show that DMF activated the NRF2 transcrip-
tional pathway inducing an anti-inflammatory shift in cir-
culating immune cell subsets in MS patients. NQO1
induction 4–6 weeks after treatment initiation correlated
with Treg frequencies in PBMC after 3 months as well as
NEDA status 1 year later.
In our cohort, DMF enhanced the frequency of Tregs
in peripheral blood during the first 3 months of treat-
ment. Although there are no numerical deficits in Treg
cells, they have repeatedly been reported to be dysfunc-
tional in MS.23,24 An increase in Treg numbers may
therefore help to compensate for a reduced functionality
and contribute to early clinical effects of DMF. Together
with Treg cells, pDC are considered to be safeguards of
peripheral T-cell tolerance and display an altered matura-
tion and regulatory function in MS.25,26 Our findings sug-
gest that DMF favors a late expansion of pDC which may
promote a tolerogenic microenvironment. Indeed, pDC
Figure 2. DMF therapy modulates the frequency of immune cell subsets in the blood of MS patients. The frequency of Treg (A), CD56bright NK
cells (B), pDC (C), mDC1 (D), mDC2 (E), CD4+ cells (F), Th1 (G), Th2 (H), Th17 (I), CD56dim NK cells (J), CD8+ T cells (K), and B cells (L) in the
peripheral blood of HD and DMF-treated MS patients as assessed by flow cytometry (9–11 HD and 10–30 DMF-treated MS patients per time
point; *P < 0.05, **P < 0.01). HD, healthy donor; baseline (T0), 4–6 weeks (T1), 3 months (T2), 6 months (T3), and 1 year (T4) of DMF intake.
Table 2. Evaluation of clinical outcome after 1 year of DMF therapy.
Clinical outcome after 1 year Patient cohort (n = 28)
Absolute lymphocyte count
T0, mean (SD) 1.9 (0.7) 9 103/lL
T4, mean (SD) 1.2 (0.5) 9 103/lL
Patients with new
lesions in MRI, n (%)
6 (21.4%)
EDSS score
T0, median (IQR) 1.5 (1.0)
T4, median (IQR) 1.5 (1.5)
Patients with relapses, n (%) 9 (32.1%)
Patients with NEDA, n (%) 9 (32.1%)
Clinically stable
(self-evaluation patient), n (%)
14 (50.0%)
SD, standard deviation; IQR, interquartile range; MRI, magnetic reso-
nance imaging; NEDA, No evidence of disease activity; EDSS,
Expanded Disability Status Scale; T0, baseline; T4, 1 year after treat-
ment onset.
Only patients who participated until the end of the study (T4) were
included (28/43).
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Figure 3. Age-dependent NQO1 induction correlates with Treg frequencies and NEDA status after 1 year of DMF therapy. Analysis of relations
between NEDA status (T4), NQO1 induction (T1), Treg frequency (T2), and patient age (T0) (18–25 DMF-treated MS patients were included in the
1 year analysis; *P < 0.05). N = no, Y = yes; baseline (T0), 4–6 weeks (T1), 3 months (T2), 6 months (T3), and 1 year (T4) of DMF intake.
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have been shown to suppress mDC-dependent induction/
expansion of CNS Th1 and Th17 cells and rather promote
Treg activation.27 Furthermore, mDC from DMF-treated
MS patients exhibit a rather immature phenotype with
reduced expression of costimulatory molecules and
impaired T-cell activation capacity.28 Lower numbers of
circulating mDC, CD8+ cytotoxic T cells and B lympho-
cytes but enhanced CD56bright NK cell frequencies in the
blood of DMF-treated MS patients further support the
concept of an anti-inflammatory shift in the peripheral
immune cell compartment probably mediated by NRF2
activation.19 Close associations between a reduction in B
lymphocytes, respectively, an increase in regulatory
CD56bright NK cells and a good response to treatment
were previously described for other immunomodulatory
drugs.29,30 Therefore, our and previous data suggest that
activation of the NRF2 transcriptional pathway and
respective regulation of specific cell types is key to achieve
a complete response to DMF in MS.
In good accordance with previously published data,
DMF treatment activates the NRF2 pathway and induces
NQO1 expression in the blood of our MS patient
cohort.31 However, in our study, the gene expression
already peaked after 4–6 weeks and was not significantly
different from baseline values after 3 months of DMF
therapy. This discrepancy might be caused by differences
in technical approaches, the patient cohort, compliance,
or study design and underlines the overall complexity of
defining the mechanism of action of this therapy. Addi-
tionally, we demonstrated a correlation between the
induction of NQO1 expression upon DMF treatment ini-
tiation and enhanced Treg frequencies as well as clinical
outcome. The fact that AKR1C1 and HO-1 induction did
not show any correlation with Treg counts or NEDA sta-
tus may indicate a diverging or cell type-specific role for
different NRF2 target genes in MS pathogenesis.
Interestingly, the chance to achieve NEDA status after
1 year of therapy was lower in older MS patients.
Reduced NQO1 induction following DMF treatment with
increasing age may explain this observation, since we
showed that activation of the NRF2 transcriptional path-
way during the first weeks of therapy is crucial for later
Treg induction and clinical outcome. Therefore, a com-
parison between peripheral NQO1 levels before treatment
onset and after 1–2 months may represent an early bio-
marker for clinical efficacy and response to DMF therapy
of the individual patient.
Due to its role in managing oxidative stress responses,
NRF2 is involved in several other autoimmune diseases
besides MS, including psoriasis, asthma, and diabetes, as
well as in neurodegeneration and different forms of can-
cer (as reviewed in 32–34). Our data further add to a
growing body of literature on how the NRF2
transcriptional pathway contributes to balance T-cell and
APC polarization during human autoimmunity in the
periphery.8,35,36 Yet, some recently published data
employing Nrf2 knockout mice suggest that the anti-
inflammatory activity of DMF in treatment of MS
patients may additionally occur through alternative path-
ways, independent of NRF2.15
Furthermore, we observed no effect of DMF intake on
the expression of the niacin receptor HCAR2. Although
HCAR2 signaling seems to be important for the efficacy
of DMF treatment in neuroinflammation,16 transcrip-
tional regulation of HCAR2 may not be relevant for DMF
therapy in MS. Additionally, Tang and colleagues already
showed that the expression of HCAR2 is rather low in
the peripheral immune system and that it may play a role
in the central nervous system instead.17
In conclusion, we demonstrated that DMF effects in
relapsing-remitting MS are paralleled by induction of the
antioxidant NRF2 transcriptional pathway and a shift
toward regulatory immune cell subsets in the periphery.
Investigating the role of NRF2 and its target genes on effi-
cacy as well as side effects of DMF therapy in larger
cohorts may further advance our understanding of its
mechanism of action and contribute to a safer treatment
of MS but also other autoimmune and neurodegenerative
diseases.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Figure S1. DMF therapy does not alter HO-1 expression
in PBMC.
Figure S2. DMF therapy modulates the absolute number
of immune cells in the blood of MS patients.
Figure S3. Induction of the NRF2 target genes does not
correlate with disability progression (EDSS) after 1 year
of DMF therapy.
Figure S4. AKR1C1 induction does not correlate with
Treg frequencies and NEDA status after 1 year of DMF
therapy.
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